Generic name: gadoversetamide
Dosage form: injection, solution
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
OptiMARK™ Injection should be administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual or by power injection.
|Body Weight||0.1 mmol/kg|
|Kilograms (kg)||Pounds (lb)||Volume (mL)|
The imaging procedure should be completed within 1 hour of the injection of OptiMARK™ Injection. The safety of repeat doses has not been studied. OptiMARK™ MRI images should be interpreted in comparison to unenhanced MRI (see CLINICAL PHARMACOLOGY, PHARMACODYNAMICS and CLINICAL TRIALS).
Parenteral products should be inspected visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present.
Concurrent medications or Parenteral Nutrition should not be physically mixed with contrast agents and should not be administered in the same intravenous line because of the potential for chemical incompatibility.
When OptiMARK™ Injection is to be injected using plastic disposable syringes, the contrast should be drawn into the syringe and used immediately.
This product has not been evaluated for use in magnetic resonance angiography.
OptiMARK™ Injection should be drawn into the syringe and administered using sterile technique. If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents. To ensure complete injection of the contrast medium the injection should be followed by a 5 mL normal saline flush. Unused portions of the drug must be discarded.